Showing results (261-270 of 617) with videos related to

Sort By:
Pageof 62
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNMPeter Valent, Karin Hartmann, Gregor Hoermann, et al.
Leukemia Research|June 19, 2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Eyal C Attar, Philip C Amrein, James W Fraser, et al.
The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
The Journal of Investigative Dermatology|February 13, 2021
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on MastocytosisElisabeth Aberer, Wolfgang R Sperr, Agnes Bretterklieber, et al.
Oncotargets and Therapy|December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomesSrdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Blood Advances|January 30, 2020
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuationGeorgia Metzgeroth, Juliana Schwaab, Nicole Naumann, et al.
Genes, Chromosomes & Cancer|February 16, 2010
Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemiaChristoph Walz, David Grimwade, Susanne Saussele, et al.
Leukemia Research|June 24, 2011
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsHarshabad Singh, Salma Asali, Lillian L Werner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
Pageof 62